R
Rachel Kerr
Researcher at University of Oxford
Publications - 87
Citations - 4889
Rachel Kerr is an academic researcher from University of Oxford. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 24, co-authored 69 publications receiving 3062 citations. Previous affiliations of Rachel Kerr include Churchill Hospital.
Papers
More filters
Journal ArticleDOI
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study.
Lennard Y W Lee,Jean-Baptiste Cazier,Vasileios Angelis,Roland Arnold,Vartika Bisht,Naomi A. Campton,Julia Chackathayil,Vinton Cheng,Helen Curley,Matthew W. Fittall,Luke Freeman-Mills,Spyridon Gennatas,Anshita Goel,Simon Hartley,D.J. Hughes,David J. Kerr,Alvin J.X. Lee,Rebecca Lee,Sophie McGrath,Christopher P. Middleton,N. Murugaesu,Thomas Newsom-Davis,Alicia Okines,Anna Olsson-Brown,Claire Palles,Yi Pan,Ruth Pettengell,Thomas Powles,Emily A. Protheroe,Karin Purshouse,Archana Sharma-Oates,Shivan Sivakumar,Ashley J. Smith,Thomas Starkey,Chris D. Turnbull,Csilla Várnai,Nadia Yousaf,Rachel Kerr,Gary Middleton +38 more
TL;DR: The clinical and demographic characteristics and COVID-19 outcomes in patients with cancer appear to be principally driven by age, gender, and comorbidities.
Journal ArticleDOI
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey,Alberto Sobrero,Anthony F. Shields,Takayuki Yoshino,James Paul,Julien Taieb,John Souglakos,Qian Shi,Rachel Kerr,Roberto Labianca,Jeffrey A. Meyerhardt,Dewi Vernerey,Takeharu Yamanaka,Ioannis Boukovinas,Jeffrey P. Meyers,Lindsay A. Renfro,Donna Niedzwiecki,Donna Niedzwiecki,Toshiaki Watanabe,Valter Torri,Valter Torri,Mark P Saunders,Daniel J. Sargent,Thierry André,Timothy Iveson +24 more
TL;DR: Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population.
Journal ArticleDOI
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.
Lee Lyw.,Cazier J-B.,Thomas Starkey,Briggs Sew.,Roland Arnold,Vartika Bisht,Stephen Booth,Naomi A. Campton,Cheng Vwt.,Gary S. Collins,Helen Curley,P Earwaker,Matthew W. Fittall,Spyridon Gennatas,Anshita Goel,Simon Hartley,D.J. Hughes,David J. Kerr,Lee Ajx.,Rebecca Lee,Siow Ming Lee,H Mckenzie,Christopher P. Middleton,N. Murugaesu,Thomas Newsom-Davis,Anna Olsson-Brown,Claire Palles,Thomas Powles,Emily A. Protheroe,Karin Purshouse,Archana Sharma-Oates,Shivan Sivakumar,A J Smith,O Topping,Chris D. Turnbull,Csilla Várnai,Briggs Adm.,Gary Middleton,Rachel Kerr +38 more
TL;DR: This study compared adult patients with cancer enrolled in the UK Coronavirus Cancer Monitoring Project between March 18 and May 8, 2020 with a parallel non-COVID-19 UK cancer control population, and analyzed the effect of primary tumour subtype, age, and sex and on severe acute respiratory syndrome coronavirus 2 prevalence and the case–fatality rate during hospital admission.
Journal ArticleDOI
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng,Tae Won Kim,Johanna C. Bendell,Guillem Argiles,Niall C. Tebbutt,Maria Di Bartolomeo,Alfredo Falcone,Marwan Fakih,Mark Kozloff,Neil H. Segal,Alberto Sobrero,Yibing Yan,Ilsung Chang,Anne Uyei,Louise Roberts,Fortunato Ciardiello,JB Ahn,J. Asselah,S Badarinath,S Baijal,S Begbie,Scott M. Berry,J-L Canon,RG Carbone,Andrés Cervantes,YJ Cha,K Chang,A Chaudhry,E Chmielowska,SH Cho,D Chu,Félix Couture,J Cultrera,David Cunningham,E. Van Cutsem,PJ Cuyle,John Davies,S Dowden,M Dvorkin,Vinod Ganju,Ruth Vera Garcia,Rachel Kerr,TY Kim,K King,J Kortmansky,M Kozloff,Ko Lam,J Lee,AS Lee,B Lesperance,Gabriele Luppi,Brigette B.Y. Ma,Evaristo Maiello,R Mandanas,John Marshall,Gavin Marx,S Mullamitha,M Nechaeva,Jo Park,Nick Pavlakis,CG Ponce,P Potemski,Sherif Raouf,James A. Jr Reeves,N Segal,Salvatore Siena,A Smolin,JO Streb,Andrew Strickland,E Szutowicz-Zielinska,Josep Tabernero,B Tan,Javier Sastre Valera,M Van den Eynde,Philippe Vergauwe,Michael M Vickers,M Womack,M Wroblewska,R. Young +78 more
TL;DR: Overall survival was overall survival in the intention-to-treat population and safety was assessed in the population of patients who received at least one dose of their assigned treatment.
Journal ArticleDOI
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.
Ole-Johan Skrede,Ole-Johan Skrede,Sepp De Raedt,Sepp De Raedt,Andreas Kleppe,Andreas Kleppe,Tarjei S. Hveem,Knut Liestøl,Knut Liestøl,John Maddison,Hanne A. Askautrud,Manohar Pradhan,John Arne Nesheim,Fritz Albregtsen,Fritz Albregtsen,I. N. Farstad,I. N. Farstad,Enric Domingo,David N. Church,David N. Church,Arild Nesbakken,Arild Nesbakken,Neil A. Shepherd,Ian Tomlinson,Ian Tomlinson,Rachel Kerr,Marco Novelli,Marco Novelli,Marco Novelli,David J. Kerr,Håvard E. Danielsen,Håvard E. Danielsen,Håvard E. Danielsen +32 more
TL;DR: The biomarker stratified stage II and III patients into sufficiently distinct prognostic groups that potentially could be used to guide selection of adjuvant treatment by avoiding therapy in very low risk groups and identifying patients who would benefit from more intensive treatment regimes.